Advertisement

The International Journal of Cardiovascular Imaging

, Volume 35, Issue 9, pp 1745–1753 | Cite as

Anti-inflammatory effect of statin is continuously working throughout use: a prospective three time point 18F-FDG PET/CT imaging study

  • Min-Kyu Kang
  • Chan Joon Kim
  • Eun-Ho Choo
  • Eun Ji Han
  • Byung-Hee Hwang
  • Jin-Jin Kim
  • Sung Hoon Kim
  • Joo Hyun O
  • Kiyuk ChangEmail author
Original Paper

Abstract

No data exist whether statins have robust anti-inflammatory effects of atherosclerotic plaques primarily during the early treatment period or continuously throughout use. This prospective three time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) study of the carotid artery assessed anti-inflammatory effects of statin during the early treatment period (initiation to 3 months) and late treatment period (3 months to 1 year) and their correlation with lipid and inflammatory profile changes during a year of therapy. Nine statin-naïve stable angina patients with inflammatory carotid plaques received 20 mg/day atorvastatin after undergoing initial 18F-FDG PET/CT scanning of carotid arteries and ascending thoracic aorta, and then completed serial 18F-FDG PET/CT imaging at 3 and 12 months whose data were analyzed. The primary outcome was the inter-scan percent change in target-to-background ratio (ΔTBR) within the index vessel. At 3 months of atorvastatin treatment, mean serum low-density lipoprotein cholesterol (LDL-C) level decreased by 36.4% to < 70 mg/dL (p = 0.001) and mean serum high-density lipoprotein cholesterol level increased to > 40 mg/dL (p = 0.041), with both maintained with no further reduction up to 1 year (p = 0.516 and 0.715, respectively) while mean serum high sensitivity C-reactive protein level only numerically decreased (p = 0.093). The index vessel ΔTBR showed continuous plaque inflammation reduction over 1 year, by 4.4% (p = 0.015) from the initiation to 3rd months and 6.2% (p = 0.009) from 3rd months to 1 year, respectively, without correlation with lipid profile changes. The ΔTBR of the bilateral carotid arteries and ascending aorta also continuously decreased from 3 months to 1 year. Three time point 18F-FDG PET/CT imaging demonstrates that statin’s anti-inflammatory effect continues throughout its use up to 1 year, even though yielding stable below-target plasma LDL-C levels at 3 months.

Keywords

Statin 18F-FDG PET/CT Low-density lipoprotein cholesterol 

Abbreviations

18F-FDG

F-18 fluorine fluorodeoxyglucose

HDL-C

High-density lipoprotein cholesterol

hs-CRP

High sensitivity C-reactive protein

LDL-C

Low-density lipoprotein cholesterol

MBq

Megabecquerel

MDS

Most diseased segment

MRI

Magnetic resonance imaging

PET/CT

Positron emission tomography/computed tomography

ROI

Region of interest

SUVmax

Maximum standardized uptake value

TBR

Target to background ratio

Notes

Funding

This study was supported by a Grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A070001).

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interests.

References

  1. 1.
    LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefPubMedGoogle Scholar
  2. 2.
    Ridker PM, Danielson E, Fonseca FAH et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMedGoogle Scholar
  3. 3.
    Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389Google Scholar
  4. 4.
    Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504.  https://doi.org/10.1056/NEJMoa040583 CrossRefPubMedGoogle Scholar
  5. 5.
    Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46:1855–1862.  https://doi.org/10.1016/j.jacc.2005.05.085 CrossRefPubMedGoogle Scholar
  6. 6.
    Davidson M, McKenney J, Stein E et al (1997) Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 79:1475–1481CrossRefPubMedGoogle Scholar
  7. 7.
    Olsson AG, Istad H, Luurila O et al (2002) Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 144:1044–1051.  https://doi.org/10.1067/mhj.2002.128049 CrossRefPubMedGoogle Scholar
  8. 8.
    Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, Abdelbaky A, Rudd JHF, Farkouh ME, Nunes IO, Beals CR, Shankar SS (2013) Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation. J Am Coll Cardiol 62:909–917.  https://doi.org/10.1016/j.jacc.2013.04.066 CrossRefPubMedGoogle Scholar
  9. 9.
    Tawakol A, Migrino RQ, Hoffmann U et al (2005) Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 12:294–301.  https://doi.org/10.1016/j.nuclcard.2005.03.002 CrossRefPubMedGoogle Scholar
  10. 10.
    Rudd JH, Myers KS, Bansilal S et al (2009) Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2:107–115.  https://doi.org/10.1161/CIRCIMAGING.108.811752 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rudd JH, Warburton EA, Fryer TD et al (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105:2708–2711.  https://doi.org/10.1161/01.CIR.0000020548.60110.76 CrossRefPubMedGoogle Scholar
  12. 12.
    Bonnet J, McPherson R, Tedgui A et al (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (comparative Atorvastatin pleiotropic effects) study. Clin Ther 30:2298–2313.  https://doi.org/10.1016/j.clinthera.2008.12.023 CrossRefPubMedGoogle Scholar
  13. 13.
    Li JJ, Fang CH, Qian HY, Hu WL (2006) Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina. Angiology 57:1–7.  https://doi.org/10.1177/000331970605700101 CrossRefPubMedGoogle Scholar
  14. 14.
    Corti R, Fayad ZA, Fuster V et al (2001) Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104:249–252.  https://doi.org/10.1161/01.CIR.104.3.249 CrossRefPubMedGoogle Scholar
  15. 15.
    Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080.  https://doi.org/10.1001/jama.291.9.1071 CrossRefPubMedGoogle Scholar
  16. 16.
    Pitt B, Waters D, Brown WV et al (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341:70–76.  https://doi.org/10.1056/NEJM199907083410202 CrossRefPubMedGoogle Scholar
  17. 17.
    Libby P (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46:1225–1228.  https://doi.org/10.1016/j.jacc.2005.07.006 CrossRefPubMedGoogle Scholar
  18. 18.
    Ridker PM, Cannon CP, Morrow D et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28.  https://doi.org/10.1056/NEJMoa042378 CrossRefPubMedGoogle Scholar
  19. 19.
    Fayad ZA, Mani V, Woodward M et al (2011) Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J 162:214–221.  https://doi.org/10.1016/j.ahj.2011.05.006 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Cardiology Division, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Cardiology Division, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaUijoenbu-siRepublic of Korea
  3. 3.Department of Radiology, Daejeon St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaDaejeonRepublic of Korea
  4. 4.Department of Radiology, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea

Personalised recommendations